La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Interpace Biosciences Résultats passés
Passé contrôle des critères 3/6
Interpace Biosciences has been growing earnings at an average annual rate of 50.7%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 9.7% per year.
Informations clés
50.7%
Taux de croissance des bénéfices
52.7%
Taux de croissance du BPA
| Healthcare Croissance de l'industrie | 8.5% |
| Taux de croissance des recettes | 9.7% |
| Rendement des fonds propres | n/a |
| Marge nette | 7.2% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Ventilation des recettes et des dépenses
Comment Interpace Biosciences gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 42 | 3 | 19 | 1 |
| 31 Mar 24 | 41 | 1 | 20 | 1 |
| 31 Dec 23 | 40 | 1 | 20 | 1 |
| 30 Sep 23 | 38 | -1 | 19 | 1 |
| 30 Jun 23 | 37 | -2 | 20 | 1 |
| 31 Mar 23 | 34 | -4 | 20 | 1 |
| 31 Dec 22 | 32 | -6 | 20 | 1 |
| 30 Sep 22 | 33 | -6 | 21 | 1 |
| 30 Jun 22 | 32 | -6 | 21 | 1 |
| 31 Mar 22 | 31 | -4 | 20 | 1 |
| 31 Dec 21 | 33 | -7 | 20 | 1 |
| 30 Sep 21 | 34 | -13 | 22 | 2 |
| 30 Jun 21 | 34 | -18 | 24 | 2 |
| 31 Mar 21 | 33 | -24 | 25 | 3 |
| 31 Dec 20 | 32 | -29 | 27 | 3 |
| 30 Sep 20 | 27 | -32 | 27 | 3 |
| 30 Jun 20 | 26 | -33 | 28 | 3 |
| 31 Mar 20 | 27 | -33 | 28 | 3 |
| 31 Dec 19 | 24 | -27 | 25 | 3 |
| 30 Sep 19 | 26 | -20 | 23 | 3 |
| 30 Jun 19 | 24 | -16 | 19 | 2 |
| 31 Mar 19 | 23 | -12 | 18 | 2 |
| 31 Dec 18 | 22 | -12 | 17 | 2 |
| 30 Sep 18 | 20 | -13 | 18 | 2 |
| 30 Jun 18 | 19 | -13 | 18 | 2 |
| 31 Mar 18 | 17 | -18 | 17 | 2 |
| 31 Dec 17 | 16 | -13 | 17 | 1 |
| 30 Sep 17 | 15 | -1 | 15 | 2 |
| 30 Jun 17 | 14 | -5 | 15 | 2 |
| 31 Mar 17 | 14 | -3 | 16 | 2 |
| 31 Dec 16 | 13 | -8 | 16 | 2 |
| 30 Sep 16 | 13 | -23 | 19 | 2 |
| 30 Jun 16 | 12 | -23 | 20 | 2 |
| 31 Mar 16 | 10 | -28 | 23 | 2 |
| 31 Dec 15 | 9 | -31 | 25 | 2 |
| 30 Sep 15 | -83 | -31 | 13 | 2 |
| 30 Jun 15 | -57 | -27 | 15 | 1 |
| 31 Mar 15 | -28 | -20 | 15 | 0 |
| 31 Dec 14 | 1 | -13 | 15 | 0 |
| 30 Sep 14 | 123 | -6 | 23 | 0 |
| 30 Jun 14 | 129 | -5 | 23 | 0 |
| 31 Mar 14 | 135 | -4 | 24 | 0 |
| 31 Dec 13 | 147 | -2 | 25 | 0 |
| 30 Sep 13 | 150 | -25 | 27 | 0 |
Des revenus de qualité: IDXG has high quality earnings.
Augmentation de la marge bénéficiaire: IDXG became profitable in the past.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: IDXG has become profitable over the past 5 years, growing earnings by 50.7% per year.
Accélération de la croissance: IDXG has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Bénéfices par rapport au secteur d'activité: IDXG has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (6%).
Rendement des fonds propres
ROE élevé: IDXG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.